Migraine drug showdown: which works better for patients?

NCT ID NCT06680206

Completed Knowledge-focused Sponsor: Pfizer Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This completed study looked at survey responses from over 1,300 people with migraine in the U.S. to compare those taking rimegepant (Nurtec) with those taking triptans. Researchers examined treatment satisfaction, quality of life, work productivity, and disability. The goal was to see if one group reported better outcomes than the other.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: rimegepant and triptans
What this could lead to: If the results show rimegepant users report better satisfaction, quality of life, or less disability, it could help doctors and patients choose between migraine treatments.
What could go wrong: This is an observational survey, not a controlled trial, so it can only show links, not cause and effect. Differences between groups may be due to other factors, not the drugs themselves.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MIGRAINE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

migraine disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MIGRAINE

Contacts and locations

Locations

Pfizer

New York, New York, 10001, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.